pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
KCP-330-009
Phase 2 · other · Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL
KCP-330-009 for Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL is a Phase 2 program (other) at Karyopharm Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code KCP-330-009
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Karyopharm Therapeutics Inc
- Phase
- Phase 2
- Modality
- other
- Indication
- Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL
- Status
- active
- Trials
- 1